Down 81.82% to C$0.01 on CNQ 16 Feb 2026: PBF.CN stock top loser insight

PBF.CN stock plunged 81.82% to C$0.01 on the CNQ during market hours on 16 Feb 2026, marking it among today’s top losers. Trading spiked to 35,000.00 shares versus an average volume of 3,347.00, a sign of thin liquidity and aggressive selling. Planet Based Foods Global Inc. (PBF.CN) is a Vancouver-based hemp-protein vegan foods maker; the sharp intraday move reflects weak market depth, poor technicals and stretched valuation signals for small-cap cannabis/plant-protein plays.

Price action and liquidity for PBF.CN stock

The share closed at C$0.01, down 81.82% on the day from a previous close of C$0.055. Volume hit 35,000.00 versus avg volume 3,347.00, producing a relative volume of 10.46, which amplified price moves in a low-market-cap name.

Market cap stands at roughly C$182,850.00 with 18,285,000.00 shares outstanding. The 50-day average was C$0.07 and the 200-day average was C$0.08, both far above today’s level, underscoring the collapse in market value.

Fundamentals and valuation for PBF.CN stock

Planet Based Foods Global Inc. reports EPS C$0.03 and a trailing PE of 0.33, but key balance metrics are weak: book value per share is negative and the current ratio is 0.06, signaling tight liquidity. Revenue per share TTM is -0.01 and operating cash flow per share TTM is -0.02, showing negative cash conversion trends.

These fundamentals drive a distorted valuation picture: low absolute price makes ratios volatile. Investors should weigh the company’s product niche in hemp-based vegan foods against low working capital and a tiny market cap in Canada’s CNQ market.

PBF.CN stock technicals and market signals

Technically the stock is oversold: RSI is 19.06 and Williams %R is -100.00, indicating extreme downward momentum. ADX at 38.27 shows a strong trend, while MACD and momentum readings are negative, supporting the intraday collapse.

Short-term supports are near the year low C$0.01 and Bollinger lower band C$0.02. Given the low liquidity, any small block trade can produce outsized moves, increasing execution risk for buyers and sellers.

Meyka AI rates PBF.CN with a score out of 100 and forecast for PBF.CN stock

Meyka AI rates PBF.CN with a score out of 100: 65.62 | Grade B | HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects mixed signals: small market cap and liquidity risk versus pockets of profitability metrics.

Meyka AI’s forecast model projects short-term rebounds and long-term variance: monthly C$0.04 (+300.00% vs current), quarterly C$0.05 (+400.00%), yearly C$0.02 (+77.49%), 3‑year C$0.00 (-72.81%), and 7‑year C$0.18 (+1,694.10%). Forecasts are model-based projections and not guarantees.

Risks and catalysts shaping PBF.CN stock

Immediate downside risk comes from liquidity and weak working capital: current ratio 0.06 and negative book value per share increase bankruptcy and dilution risk. The healthcare/drug-manufacturing sector has negative 1D performance of -6.24%, adding sector pressure.

Potential catalysts include distribution deals, cost cuts or stronger retail sales for hemp-protein lines. Any credible funding or partnership news could swing sentiment sharply given the low float and high relative volume.

Price targets, analyst consensus and trading guidance for PBF.CN stock

No formal price target consensus exists for PBF.CN. Using scenario analysis we set illustrative targets: conservative C$0.02 (implied +100.00%), base-case C$0.05 (implied +400.00%), and bull-case C$0.18 (implied +1,700.00%). These targets assume no immediate dilution and successful execution on retail expansion.

Traders should set tight size limits and use limit orders because the stock trades thinly on the CNQ in Canada. Risk management is critical: stop-losses and position-size caps mitigate outsized slippage.

Final Thoughts

PBF.CN stock’s intraday fall to C$0.01 on 16 Feb 2026 highlights the twin problems of thin liquidity and fragile fundamentals in small-cap plant-protein names. The company posts EPS C$0.03 and a PE of 0.33, but negative book equity, a current ratio of 0.06, and negative operating cash flow per share raise solvency concerns. Meyka AI rates PBF.CN 65.62/100 (Grade B, HOLD) and issues model-based forecasts that range from monthly C$0.04 to a seven-year C$0.18. Using the quarterly forecast C$0.05 implies +400.00% vs today’s price, while the three-year projection implies downside. Forecasts are model-based projections and not guarantees. For investors, the stock is a high-volatility, high-execution-risk name best suited to speculative allocations, not core positions. Check liquidity and potential dilution before entering, and follow official company updates and credible news sources for any funding or partnership announcements. For a live quote and deeper metrics, see the Meyka PBF.CN page and news links below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.